Results in Teens

DUPIXENT Demonstrated Results and Safety

DUPIXENT was studied in a 16-week clinical trial with 251 patients* ages 12-17 with
moderate-to-severe eczema not adequately controlled with topical prescription treatments.

What You Should Know About the Patients in This Study:

46%
had moderate atopic dermatitis
54%
had severe atopic dermatitis
≈15 years
Average age
≈57%
Average body surface area involvement
≈92%
Had at least one other allergic condition

In a 16-week clinical trial of teens ages 12-17, significantly more taking DUPIXENT saw:

75% skin improvement
(42% vs 8% in those not taking it)
Clear or almost clear skin
(24% vs 2% in those not taking it)
Significant itch reduction
(37% vs 5% in those not taking it)

The safety results of DUPIXENT observed in adolescents were consistent with what was seen in adults
with atopic dermatitis. The most common side effects include injection site reactions, eye and eyelid
inflammation, including redness, swelling and itching, and cold sores in your mouth or on your lips.


*Patients who weighed ≥60 kg received DUPIXENT 300 mg every two weeks after an initial dose of 600 mg, and
patients who weighed ≤60 kg received DUPIXENT 200 mg every two weeks after an initial dose of 400 mg

Find a Specialist Who
Treats Eczema

Use this Healthgrades™ tool to easily find nearby specialists with experience in treating teens and adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).

Have an Effective Conversation With
Your Doctor

Our goal is for you to get the most out of your visit to the doctor. Download the discussion guide for tips on how to drive a productive conversation.

Doctor Discussion Guide 234 KB